Ceftaroline is a new cephalosporin with bactericidal activity against resistant Gram-positive organisms, including methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pneumoniae, as well as common Gram-negative organisms. This study tested the prodrug, ceftaroline fosamil, against a penicillin-sensitive and a penicillin-resistant strain of S. pneumoniae in an experimental rabbit meningitis model. The penetration of ceftaroline into inflamed meninges was approximately 14%. Ceftaroline fosamil was slightly superior to ceftriaxone against the penicillinsensitive strain and significantly superior to the combination of ceftriaxone and vancomycin against the penicillinresistant strain.
T
he continuous spread of penicillin-resistant pneumococci remains a major challenge for clinicians and infectious disease specialists worldwide. In Spain and Portugal, approximately 10% to 25% of the pneumococcal strains are resistant to penicillin. In France, the resistance rates have reached 25% to 50% based on a European Antimicrobial Resistance Surveillance System survey in 2007 (1) .
The guidelines suggest treating meningitis caused by penicillin-resistant pneumococci with a combination of ceftriaxone and vancomycin (2) . However, because of the variable penetration of vancomycin into meninges, antimicrobial monotherapy would represent a major treatment advantage. The aim of this study was to test ceftaroline as monotherapy against a penicillin-sensitive and a penicillin-resistant strain of Streptococcus pneumoniae in the rabbit experimental meningitis model.
MATERIALS AND METHODS
Strains and microbiology. The penicillin-sensitive strain (13.05.42) and the penicillin-resistant strain (WB4) of S. pneumoniae were kindly provided by the Institute for Infectious Diseases, University of Bern (Bern, Switzerland). The strains were isolated in blood cultures from patients at the university hospital. All strains were grown in Mueller-Hinton broth and stored at Ϫ80°C after several passages in rabbits. MICs were determined by agar dilution according to the published literature (3) . Inocula for use in rabbit infection studies were prepared from stocks stored at Ϫ80°C.
Study drugs. The prodrug form of ceftaroline, ceftaroline fosamil (602 g/mg), was used for in vivo studies, and microbiologically active ceftaroline (lot number FMD-CEF-019; 813 g/mg) was used for in vitro studies. Ceftaroline and ceftaroline fosamil were obtained from Forest Laboratories, Inc., New York, NY. Vancomycin and ceftriaxone were commercially obtained and were used according to the manufacturer's recommendations and guidelines.
Experimental meningitis model. The experimental rabbit meningitis model described by Dacey and Sande (4) was employed in this study. The experimental protocols were approved by the Kantonales Veterinäramt des Kantons Bern. Pathogen-free New Zealand rabbits were provided by the Zentral Tierställe der Medizinischen Fakultät der Universität Bern, where all the experiments were performed. One day before the experiment, the rabbits were anesthetized with intramuscular injections of ketamine (30 mg/kg of body weight) and xylazine (15 mg/kg) and fitted with prostheses on their calvaria to facilitate subsequent placement within a stereotactic frame. On the day of the experiment, the rabbits received ethylcarbamate (1.75 g/kg) by subcutaneous injection and pentobarbital (10 mg/kg) by intravenous (i.v.) injection to induce deep anesthesia. The animals were fixed in a stereotactic frame, and a 3.5-in. (25G) spinal needle was introduced into the cisterna magna. Following the withdrawal of 0.2 ml of cerebrospinal fluid (CSF), the test bacteria (penicillin-sensitive or -resistant S. pneumoniae; 1 ϫ 10 5 CFU in 0.2 ml of saline solution) were injected into the subarachnoid space. After inoculation, the animals were brought back to the cages for the night. The next day, the rabbits were again fitted in the frames using the techniques and anesthesia described above. A catheter was fixed in the femoral artery for serum sampling. A spinal needle was fixed again in the subarachnoid space. Eight hours after inoculation, ceftaroline fosamil 40 mg/kg i.v. (n ϭ 10) was injected at hours 0 and 4. The comparator regimen, ceftriaxone 100 mg/kg i.v. (n ϭ 10), was administered at hour 0 for the penicillin-sensitive strain. For the penicillin-resistant strain, ceftriaxone 100 mg/kg i.v. at hour 0 plus vancomycin 20 mg/kg i.v. (n ϭ 10) at hours 0 and 4 were administered as previously described (5, 6). There was an untreated control group for each strain (n ϭ 5).
Determination of antibiotic levels and CFU titers. CSF (0.2 ml) was sampled at 0, 1, 2, 4, 6, and 8 h after initiation of therapy. Blood was sampled at 0.25, 0.5, 1, 2, 3, 4, 4.25, 4.5, 5, 6, 7, and 8 h. The ceftaroline concentrations in serum and CSF were determined by diffusion microbioassays using agar plates containing Bacillus subtilis (sus-1-A) at 10 6 CFU/0.1 ml (Raven Biological Laboratories, Inc., Omaha, NE). The limit of detection was 0.2 mg/liter for ceftaroline. The number of CFU per milliliter was determined by serial dilution of CSF and plating on agar plates with incubation overnight at 37°C. The limit of bacterial detection of this assay was estimated to be 50 CFU/ml (1.7 log 10 ). Penetration into the CSF was determined by comparing areas under the concentration versus time curves (AUC) for serum and CSF, using GraphPad Prism software (Graphpad Software Inc., San Diego, CA).
Statistical analysis. The Student t test and one-way analysis of variance (Tukey-Cramer multiple-comparison test) were used for parametric data. Comparison of positive and negative cultures was analyzed by the two-tailed Fisher exact test. A P value of Ͻ0.05 was considered significant.
The efficacies of the different regimens are presented as ⌬log 10 CFU/ ml/hour and as ⌬log 10 CFU/ml/8 h. A value of 1.7 log 10 CFU/ml was assigned to the first sterile CSF sample (the limit of detection) and a value of 0 to each subsequent sterile CSF sample. Figure 1 shows the serum levels of ceftaroline in rabbits with inflamed meninges. Approximately 15 min after one injection of 40 mg/kg of ceftaroline fosamil, the peak serum level reached approximately 60 mg/liter, decreasing to 4 mg/liter 4 h later. In the CSF, the ceftaroline levels increased rapidly to 3.2 mg/liter after 1 h and decreased slowly to 1.6 mg/liter at hour 4. After the second injection, ceftaroline levels peaked at approximately 3.8 mg/liter and decreased slowly to 1.8 mg/liter at the end of the treatment period (Fig. 2) . Ceftaroline penetration into the CSF was 14% in the present study. The pharmacokinetics and CSF penetration observed here were similar to those in a previous study with Escherichia coli and Klebsiella pneumoniae in this rabbit model (unpublished data). The kinetics of the comparator regimens, i.e., ceftriaxone against the penicillin-sensitive strain and ceftriaxone combined with vancomycin against the penicillin-resistant strain, were not determined because they were applied in standard doses, which have been used routinely in this model in the past.
RESULTS AND DISCUSSION
The MICs of ceftaroline for the penicillin-sensitive and -resistant strains of S. pneumoniae were 0.007 mg/liter and 0.12 mg/ liter, respectively, while the ceftriaxone MICS were 0.05 mg/liter and 0.5 mg/liter, respectively. The MIC of vancomycin against penicillin-resistant S. pneumoniae was 0.12 mg/liter.
The in vivo efficacies of ceftaroline fosamil and both comparator agents are summarized in Tables 1 and 2 . Ceftaroline fosamil and ceftriaxone exhibited comparable bactericidal activities against the penicillin-sensitive strain, based on the killing rates per hour; however, the killing rates of ceftaroline were significantly superior to those of ceftriaxone at the end of the study (P Ͻ 0.03) ( Table 1) . Over the 8-hour treatment period, ceftaroline fosamil demonstrated significantly higher killing rates against the penicillin-resistant strain of S. pneumoniae than the combination of ceftriaxone and vancomycin (P Ͻ 0.03) ( Table 2) .
Ceftriaxone monotherapy was less efficacious against the same penicillin-resistant strain in two previous studies, with lower killing rates per hour (Ϫ0.31 log 10 CFU/ml), probably due to the lower MIC of ceftaroline for the strain (5, 6). As expected, ceftriaxone and ceftaroline produced similar bactericidal activities against the penicillin-sensitive S. pneumoniae strain, despite their different MICs. Ceftaroline was very efficacious against a penicillin-resistant pneumococcal strain and was superior to the standard regimen of ceftriaxone plus vancomycin in this experimental meningitis model. In summary, in this rabbit in vivo model, ceftaroline penetration into inflamed meninges and levels in the CSF were sufficient to provide bactericidal activity against penicillin-sensitive and -resistant S. pneumoniae isolates. Ceftaroline fosamil may be an option for first-line therapy, especially when penicillin-resistant strains are suspected, and additional studies of ceftaroline in meningitis are warranted. 
